. . "1"^^ . "A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate" . . "Sedl\u00E1\u010Dkov\u00E1, Marie" . "A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate"@en . "RIV/00064190:_____/14:#0000736" . "2"^^ . . "1"^^ . . "Bristol-Myers Squibb, spol. s r.o." . "A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate" . . "A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate"@en . . . "RIV/00064190:_____/14:#0000736!RIV14-MZ0-00064190" . "1032" . "N" . "[D639085A4613]" . . "The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to methotrexate in the treatment of moderate to severe Rheumatoid Arthritis Secondary objectives of the trial ACR 50 ACR 70 Disease Activity Score-c Reactive Protein (DAS-CRP) Clinical Disease Activity Index Physical Function Magnetic Resonance Imaging (MRI) X-Ray Health Related Quality of Life outcomes Safety (number of adverse events)" . . . "Praha" . . . "The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to methotrexate in the treatment of moderate to severe Rheumatoid Arthritis Secondary objectives of the trial ACR 50 ACR 70 Disease Activity Score-c Reactive Protein (DAS-CRP) Clinical Disease Activity Index Physical Function Magnetic Resonance Imaging (MRI) X-Ray Health Related Quality of Life outcomes Safety (number of adverse events)"@en . "Rheumatoid Arthritis"@en .